<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052065</url>
  </required_header>
  <id_info>
    <org_study_id>TLK286.2011</org_study_id>
    <nct_id>NCT00052065</nct_id>
  </id_info>
  <brief_title>TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer</brief_title>
  <official_title>Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Telik</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Telik</source>
  <brief_summary>
    <textblock>
      This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in
      patients with platinum refractory or resistant ovarian cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>28</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TLK286</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Histologically or cytologically confirmed diagnosis of epithelial cancer of the ovary,
             fallopian tube cancer or primary peritoneal cancer

          -  Recurrent epithelial ovarian cancer or persistent disease following primary treatment

          -  At least one, but no more than four, prior platinum-containing chemotherapy regimens

          -  At least one prior taxane-containing regimen

        Exclusion Criteria

          -  A history of prior malignancy except for adequately treated carcinoma in situ of the
             uterine cervix, basal cell or squamous cell skin cancer, or other cancer for which the
             patient has been disease-free for 2 years

          -  Known leptomeningeal metastases or carcinomatous meningitis

          -  Have received prior Doxil or other liposomal doxorubicin

          -  Having received whole pelvis radiation therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2003</study_first_submitted>
  <study_first_submitted_qc>January 22, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2003</study_first_posted>
  <last_update_submitted>July 21, 2011</last_update_submitted>
  <last_update_submitted_qc>July 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Gail Brown, M.D. Chief Medical Officer</name_title>
    <organization>Telik, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

